https://www.selleckchem.com/pr....oducts/xl413-bms-863
umulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 33 in the SB11 group and 3.1% (10 of 327) in the ranibizumab group. These findings of equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab support the use of SB11 for patients with neovascular age-related macular degeneration. ClinicalTrials.gov Identifier NCT03150589. ClinicalTrials.gov Identifier NCT03150589. Critically ill patients with coronavirus disease 2019 (COVID-19) who are unresponsive to maximum optimal v
Like
Comment
Share
